Pfenex, Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2009)
Status: Acquired by Ligand Pharmaceuticals (2020)

Organization Overview

First Clinical Trial
2013
NCT02121353
First Marketed Drug
2019
teriparatide
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PFENEX INC

Active Ingredients

Marketed Drugs (1)

teriparatide (2019)

Drugs in Phase 3 Trials (1)

teriparatide (2 trials)

Drugs in Phase 2 Trials (1)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 1 Trials (3)

interferon beta-1b (betaseron) (1 trial)

px563l (1 trial)

rpa563 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 1)

Macular Degeneration (Phase 2)

Multiple Sclerosis (Phase 1)

Osteoporosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5